Giampiero Spalluto

List of Publications by Year
in descending order

135	6,151	87888	76900
papers	citations	38 h-index	74 g-index

146	146	146	6226
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Glycogen Synthase Kinase 3Î² Involvement in Neuroinflammation and Neurodegenerative Diseases. Current Medicinal Chemistry, 2022, 29, 4631-4697.	2.4	14
2	Potent and selective A₃ adenosine receptor antagonists bearing aminoesters as heterobifunctional moieties. RSC Medicinal Chemistry, 2021, 12, 254-262.	3.9	0
3	Developing novel classes of protein kinase CK1Î´ inhibitors by fusing [1,2,4]triazole with different bicyclic heteroaromatic systems. European Journal of Medicinal Chemistry, 2021, 216, 113331.	5.5	9
4	Conjugable A3 adenosine receptor antagonists for the development of functionalized ligands and their use in fluorescent probes. European Journal of Medicinal Chemistry, 2020, 186, 111886.	5.5	11
5	Targeting G Proteinâ€Coupled Receptors with Magnetic Carbon Nanotubes: The Case of the A 3 Adenosine Receptor. ChemMedChem, 2020, 15, 1909-1920.	3.2	4
6	Design, Synthesis and Evaluation of New Indolylpyrimidylpiperazines for Gastrointestinal Cancer Therapy. Molecules, 2019, 24, 3661.	3.8	0
7	The current status of pharmacotherapy for the treatment of Parkinsonâ€™s disease: transition from single-target to multitarget therapy. Drug Discovery Today, 2019, 24, 1769-1783.	6.4	46
8	Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidines to develop functionalized ligands to target adenosine receptors: fluorescent ligands as an example. MedChemComm, 2019, 10, 1094-1108.	3.4	9
9	Chemical Probes for the Adenosine Receptors. Pharmaceuticals, 2019, 12, 168.	3.8	10
10	Functionalized ligands targeting G protein-coupled adenosine receptors. Future Medicinal Chemistry, 2019, 11, 1673-1677.	2.3	4
11	A Triazolotriazineâ€Based Dual GSKâ€3Î²/CKâ€1Î´ Ligand as a Potential Neuroprotective Agent Presenting Two Different Mechanisms of Enzymatic Inhibition. ChemMedChem, 2019, 14, 310-314.	3.2	22
12	Structure Activity Relationship of 4-Amino-2-thiopyrimidine Derivatives as Platelet Aggregation Inhibitors. Medicinal Chemistry, 2019, 15, 863-872.	1.5	4
13	Targeting Protein Kinase CK1Î´ with Riluzole: Could It Be One of the Possible Missing Bricks to Interpret Its Effect in the Treatment of ALS from a Molecular Point of View?. ChemMedChem, 2018, 13, 2601-2605.	3.2	16
14	[1,2,4]Triazolo[1,5-c]pyrimidines as adenosine receptor antagonists: Modifications at the 8 position to reach selectivity towards A3 adenosine receptor subtype. European Journal of Medicinal Chemistry, 2018, 157, 837-851.	5.5	13
15	Discovery of indolylpiperazinylpyrimidines with dual-target profiles at adenosine A2A and dopamine D2 receptors for Parkinson's disease treatment. PLoS ONE, 2018, 13, e0188212.	2.5	23
16	A2A Adenosine Receptor Antagonists as Therapeutic Candidates: Are They Still an Interesting Challenge?. Mini-Reviews in Medicinal Chemistry, 2018, 18, 1168-1174.	2.4	15
17	Conjugates between minor groove binders and Zn(II)-tach complexes: Synthesis, characterization, and interaction with plasmid DNA. Tetrahedron, 2017, 73, 3014-3024.	1.9	5
18	Impact of proteinâ€“ligand solvation and desolvation on transition state thermodynamic properties of adenosine A2A ligand binding kinetics. In Silico Pharmacology, 2017, 5, 16.	3.3	20

#	Article	IF	Citations
19	5,7-Disubstituted-[1,2,4]triazolo[1,5- a][1,3,5]triazines as pharmacological tools to explore the antagonist selectivity profiles toward adenosine receptors. European Journal of Medicinal Chemistry, 2016, 108, 529-541.	5.5	18
20	Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidines and Structurally Simplified Analogs. Chemistry and SAR Profile as Adenosine Receptor Antagonists. Current Topics in Medicinal Chemistry, 2016, 16, 3224-3257.	2.1	13
21	Advances in Computational Techniques to Study GPCRâ€“Ligand Recognition. Trends in Pharmacological Sciences, 2015, 36, 878-890.	8.7	40
22	The Influence of the 1-(3-Trifluoromethyl-Benzyl)-1H-Pyrazole-4-yl Moiety on the Adenosine Receptors Affinity Profile of Pyrazolo[4,3-e][1,2,4]Triazolo[1,5-c]Pyrimidine Derivatives. PLoS ONE, 2015, 10, e0143504.	2.5	6
23	Scaffold Decoration at Positions 5 and 8 of 1,2,4-Triazolo[1,5-c]Pyrimidines to Explore the Antagonist Profiling on Adenosine Receptors: A Preliminary Structureâ€“Activity Relationship Study. Journal of Medicinal Chemistry, 2014, 57, 6210-6225.	6.4	13
24	Discovery of simplified N2-substituted pyrazolo[3,4-d]pyrimidine derivatives as novel adenosine receptor antagonists: Efficient synthetic approaches, biological evaluations and molecular docking studies. Bioorganic and Medicinal Chemistry, 2014, 22, 1751-1765.	3.0	16
25	The A₃ adenosine receptor as multifaceted therapeutic target: pharmacology, medicinal chemistry, and in silico approaches. Medicinal Research Reviews, 2013, 33, 235-335.	10.5	38
26	8-(2-Furyl)adenine derivatives as A2A adenosine receptor ligands. European Journal of Medicinal Chemistry, 2013, 70, 525-535.	5.5	14
27	Fluorescent ligands for adenosine receptors. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 26-36.	2.2	28
28	Revisiting a Receptor-Based Pharmacophore Hypothesis for Human A_{2A} Adenosine Receptor Antagonists. Journal of Chemical Information and Modeling, 2013, 53, 1620-1637.	5.4	16
29	Exploring the Directionality of 5-Substitutions in a New Series of 5-Alkylaminopyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine as a Strategy To Design Novel Human A₃ Adenosine Receptor Antagonists.. Journal of Medicinal Chemistry, 2012, 55, 9654-9668.	6.4	17
30	A Novel Conjugated Agent between Dopamine and an A_{2A} Adenosine Receptor Antagonist as a Potential Anti-Parkinson Multitarget Approach. Molecular Pharmaceutics, 2012, 9, 591-604.	4.6	29
31	Therapeutic potential of A₂and A₃adenosine receptor: a review of novel patented ligands. Expert Opinion on Therapeutic Patents, 2012, 22, 369-390.	5.0	17
32	Novel fluorescent antagonist as a molecular probe in A3 adenosine receptor binding assays using flow cytometry. Biochemical Pharmacology, 2012, 83, 1552-1561.	4.4	33
33	Synthesis and Biological Evaluation of a New Series of 1,2,4-Triazolo[1,5-a]-1,3,5-triazines as Human A_{2A} Adenosine Receptor Antagonists with Improved Water Solubility. Journal of Medicinal Chemistry, 2011, 54, 877-889.	6.4	30
34	Does the combination of optimal substitutions at the C2-, N5- and N8-positions of the pyrazolo-triazolo-pyrimidine scaffold guarantee selective modulation of the human A3 adenosine receptors?. Bioorganic and Medicinal Chemistry, 2011, 19, 6120-6134.	3.0	11
35	Pharmacophore elucidation for a new series of 2-aryl-pyrazolo-triazolo-pyrimidines as potent human A3 adenosine receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 2898-2905.	2.2	14
36	New 9-methyl-8-(4-hydroxyphenyl)adenine derivatives as A1 adenosine receptor antagonists. Collection of Czechoslovak Chemical Communications, 2011, 76, 1379-1393.	1.0	8

#	Article	IF	Citations
37	Pyrazolo Derivatives as Potent Adenosine Receptor Antagonists: An Overview on the Structure-Activity Relationships. International Journal of Medicinal Chemistry, 2011, 2011, 1-15.	2.2	6
38	The Significance of 2-Furyl Ring Substitution with a 2-(para-substituted) Aryl Group in a New Series of Pyrazolo-triazolo-pyrimidines as Potent and Highly Selective hA₃ Adenosine Receptors Antagonists: New Insights into Structureâ"Affinity Relationship and Receptorâ"Antagonist Recognition. Journal of Medicinal Chemistry, 2010, 53, 3361-3375.	6.4	40
39	Synthesis and pharmacological characterization of a new series of 5,7-disubstituted-[1,2,4]triazolo[1,5-a][1,3,5]triazine derivatives as adenosine receptor antagonists: A preliminary inspection of ligandâ€"receptor recognition process. Bioorganic and Medicinal Chemistry, 2010, 18, 2524-2536.	3.0	29
40	Receptor-Driven Identification of Novel Human A3 Adenosine Receptor Antagonists as Potential Therapeutic Agents. Methods in Enzymology, 2010, 485, 225-244.	1.0	7
41	Carbon Nanotubes Carrying Cellâ€Adhesion Peptides do not Interfere with Neuronal Functionality. Advanced Materials, 2009, 21, 2903-2908.	21.0	67
42	Combining selectivity and affinity predictions using an integrated Support Vector Machine (SVM) approach: An alternative tool to discriminate between the human adenosine A2A and A3 receptor pyrazolo-triazolo-pyrimidine antagonists binding sites. Bioorganic and Medicinal Chemistry, 2009, 17, 5259-5274.	3.0	26
43	6-Amino-2-mercapto-3H-pyrimidin-4-one derivatives as new candidates for the antagonism at the P2Y12 receptors. Bioorganic and Medicinal Chemistry, 2009, 17, 4612-4621.	3.0	39
44	Exploring Potency and Selectivity Receptor Antagonist Profiles Using a Multilabel Classification Approach: The Human Adenosine Receptors as a Key Study. Journal of Chemical Information and Modeling, 2009, 49, 2820-2836.	5.4	19
45	Human A3 Adenosine Receptor as Versatile G Protein-Coupled Receptor Example to Validate the Receptor Homology Modeling Technology. Current Pharmaceutical Design, 2009, 15, 4069-4084.	1.9	10
46	Pyrazolo-triazolo-pyrimidines as adenosine receptor antagonists: Effect of the N-5 bond type on the affinity and selectivity at the four adenosine receptor subtypes. Purinergic Signalling, 2008, 4, 39-46.	2.2	10
47	Linear and Nonlinear 3D-QSAR Approaches in Tandem with Ligand-Based Homology Modeling as a Computational Strategy To Depict the Pyrazolo-Triazolo-Pyrimidine Antagonists Binding Site of the Human Adenosine A_{2A} Receptor. Journal of Chemical Information and Modeling, 2008, 48, 350-363.	5.4	30
48	Response Surface Analysis as Alternative 3D-QSAR Tool: Human A3 Adenosine Receptor Antagonists as a Key Study. Letters in Drug Design and Discovery, 2007, 4, 122-127.	0.7	6
49	Highlights on the Development of A2A Adenosine Receptor Agonists and Antagonists. ChemMedChem, 2007, 2, 260-281.	3.2	38
50	Pyrazolo-triazolo-pyrimidines as adenosine receptor antagonists: A complete structureâ€"activity profile. Purinergic Signalling, 2007, 3, 183-193.	2.2	18
51	New 2,6,9-trisubstituted adenines as adenosine receptor antagonists: a preliminary SAR profile. Purinergic Signalling, 2007, 3, 339-346.	2.2	12
52	Facile and Versatile Route to the Synthesis of Fused 2â€Pyridones: Useful Intermediates for Polycyclic Sytems. Synthetic Communications, 2006, 36, 1173-1183.	2.1	8
53	Synthesis and Biological Studies of a New Series of 5-Heteroarylcarbamoylaminopyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines as Human A3Adenosine Receptor Antagonists. Influence of the Heteroaryl Substituent on Binding Affinity and Molecular Modeling Investigations. Journal of Medicinal Chemistry, 2006, 49, 1720-1729.	6.4	27
54	G protein-coupled receptors as challenging druggable targets: insights from in silico studies. New Journal of Chemistry, 2006, 30, 301.	2.8	19

#	Article	IF	Citations
55	A3 adenosine receptor antagonists delay irreversible synaptic failure caused by oxygen and glucose deprivation in the rat CA1 hippocampus in vitro. British Journal of Pharmacology, 2006, 147, 524-532.	5.4	71
56	The application of a 3D-QSAR (autoMEP/PLS) approach as an efficient pharmacodynamic-driven filtering method for small-sized virtual library: Application to a lead optimization of a human A3 adenosine receptor antagonist. Bioorganic and Medicinal Chemistry, 2006, 14, 4923-4932.	3.0	29
57	Progress in the pursuit of therapeutic adenosine receptor antagonists. Medicinal Research Reviews, 2006, 26, 131-159.	10.5	154
58	Ligand-Based Homology Modeling as Attractive Tool to Inspect GPCR Structural Plasticity. Current Pharmaceutical Design, 2006, 12, 2175-2185.	1.9	80
59	Potent and Selective A2A Adenosine Receptor Antagonists: Recent Improvements. Frontiers in Drug Design and Discovery, 2005, 2, 49-62.	0.3	0
60	Synthesis and biological evaluation of new phenidone analogues as potential dual cyclooxygenase (COX-1 and COX-2) and human lipoxygenase (5-LOX) inhibitors. Il Farmaco, 2005, 60, 7-13.	0.9	9
61	Synthesis and biological evaluation of a new class of acyl derivatives of 3-amino-1-phenyl-4,5-dihydro-1H-pyrazol-5-one as potential dual cyclooxygenase (COX-1 and COX-2) and human lipoxygenase (5-LOX) inhibitors. Il Farmaco, 2005, 60, 327-332.	0.9	17
62	Synthesis, biological studies and molecular modeling investigation of 1,3-dimethyl-2,4-dioxo-6-methyl-8-(substituted) 1,2,3,4-tetrahydro [1,2,4]-triazolo [3,4-f]-purines as potential adenosine receptor antagonists. Il Farmaco, 2005, 60, 299-306.	0.9	7
63	Synthesis and Biological Evaluation of New Phenidone Analogues as Potential Dual Cyclooxygenase (COX-1 and COX-2) and Human Lipoxygenase (5-LOX) Inhibitors.. ChemInform, 2005, 36, no.	0.0	0
64	Synthesis, Biological Studies and Molecular Modeling Investigation of 1,3-Dimethyl-2,4-dioxo-6-methyl-8-(substituted) 1,2,3,4-Tetrahydro-[1,2,4]-triazolo-[3,4-f]-purines as Potential Adenosine Receptor Antagonists.. ChemInform, 2005, 36, no.	0.0	0
65	Anti-HIV properties of cationic fullerene derivatives. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 3615-3618.	2.2	133
66	A2B Adenosine Receptor Antagonists: Recent Developments. Mini-Reviews in Medicinal Chemistry, 2005, 5, 1053-1060.	2.4	32
67	Non Peptidic αvβ3 Antagonists: Recent Developments. Current Medicinal Chemistry, 2005, 12, 51-70.	2.4	50
68	Autocorrelation of Molecular Electrostatic Potential Surface Properties Combined with Partial Least Squares Analysis as Alternative Attractive Tool to Generate Ligand-Based 3D-QSARs. Current Drug Discovery Technologies, 2005, 2, 13-21.	1.2	71
69	Autocorrelation of Molecular Electrostatic Potential Surface Properties Combined with Partial Least Squares Analysis as New Strategy for the Prediction of the Activity of Human A3Adenosine Receptor Antagonists. Journal of Medicinal Chemistry, 2005, 48, 5698-5704.	6.4	38
70	Techniques: Recent developments in computer-aided engineering of GPCR ligands using the human adenosine A3 receptor as an example. Trends in Pharmacological Sciences, 2005, 26, 44-51.	8.7	72
71	Combined Target-Based and Ligand-Based Drug Design Approach as a Tool To Define a Novel 3D-Pharmacophore Model of Human A3 Adenosine Receptor Antagonists:â€‰ Pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine Derivatives as a Key Study. Journal of Medicinal Chemistry, 2005, 48, 152-162.	6.4	69
72	Carbon Nanotube Substrates Boost Neuronal Electrical Signaling. Nano Letters, 2005, 5, 1107-1110.	9.1	614

#	Article	IF	Citations
73	Synthesis and anti-HIV Properties of New Water-Soluble Bis-functionalized[60]fullerene Derivatives.. ChemInform, 2004, 35, no.	0.0	0
74	Fullerene Derivatives: An Attractive Tool for Biological Applications. ChemInform, 2004, 35, no.	0.0	1
75	Synthesis of Pyridazine Derivatives Through the Unexpected Intermediate 5-Amino-4-cyano-2,3-dihydro-furan-2,3-disulfonic Acid Disodium Salt.. ChemInform, 2004, 35, no.	0.0	0
76	Hemolytic Effects of Water-Soluble Fullerene Derivatives. Journal of Medicinal Chemistry, 2004, 47, 6711-6715.	6.4	114
77	Synthesis of pyridazine derivatives through the unexpected intermediate 5â€aminoâ€•4â€cyano â€2,3â€dihydroâ€furanâ€2,3â€disulfonic acid disodium salt. Journal of Heterocyclic Chemistry, 2003, 40, 1065-1069.	2.6	9
78	Synthesis and Anti-HIV properties of new water-soluble bis-functionalized[60]fullerene derivatives. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 4437-4440.	2.2	114
79	Fullerene derivatives: an attractive tool for biological applications. European Journal of Medicinal Chemistry, 2003, 38, 913-923.	5.5	780
80	Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine Derivatives as Adenosine Receptor Antagonists. Influence of the N5 Substituent on the Affinity at the Human A3and A2BAdenosine Receptor Subtypes:Â A Molecular Modeling Investigation. Journal of Medicinal Chemistry, 2003, 46, 4287-4296.	6.4	55
81	Demystifying the three dimensional structure of G protein-coupled receptors (GPCRs) with the aid of molecular modeling. Chemical Communications, 2003, , 2949.	4.1	38
82	Medicinal Chemistry of A2A Adenosine Receptor Antagonists. Current Topics in Medicinal Chemistry, 2003, 3, 403-411.	2.1	43
83	7-Substituted 5-Amino-2-(2-furyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as A2AAdenosine Receptor Antagonists:Â A Study on the Importance of Modifications at the Side Chain on the Activity and Solubility. Journal of Medicinal Chemistry, 2002, 45, 115-126.	6.4	101
84	Synthesis, Biological Properties, and Molecular Modeling Investigation of the First Potent, Selective, and Water-Soluble Human A3 Adenosine Receptor Antagonist. Journal of Medicinal Chemistry, 2002, 45, 3579-3582.	6.4	74
85	Pyrazolo-Triazolo-Pyrimidine Derivatives as Adenosine Receptor Antagonists: A Possible Template for Adenosine Receptor Subtypes?. Current Pharmaceutical Design, 2002, 8, 2299-2332.	1.9	26
86	Synthesis, Biological Activity, and Molecular Modeling Investigation of New Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine Derivatives as Human A3 Adenosine Receptor Antagonists. Journal of Medicinal Chemistry, 2002, 45, 770-780.	6.4	99
87	A New Multi-Charged C60 Derivative: Synthesis and Biological Properties. European Journal of Organic Chemistry, 2002, 2002, 2928-2934.	2.4	44
88	Synthesis and Molecular Modeling Studies of Fullereneâ^'5,6,7-Trimethoxyindoleâ^'Oligonucleotide Conjugates as Possible Probes for Study of Photochemical Reactions in DNA Triple Helices. European Journal of Organic Chemistry, 2002, 2002, 405-413.	2.4	26
89	Design, synthesis and biological properties of fulleropyrrolidine derivatives as potential DNA photo-probes. Journal of Supramolecular Chemistry, 2002, 2, 327-334.	0.4	10
90	Fluorosulfonyl- and Bis-(Î²-chloroethyl)amino-phenylamino Functionalized Pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine Derivatives:â€‰ Irreversible Antagonists at the Human A3 Adenosine Receptor and Molecular Modeling Studies. Journal of Medicinal Chemistry, 2001, 44, 2735-2742.	6.4	37

#	Article	IF	Citations
91	Current Chemistry: Fullerene Derivatives as Potential DNA Photoprobes. Australian Journal of Chemistry, 2001, 54, 223.	0.9	14
92	DNA-Photocleavage Agents. Current Pharmaceutical Design, 2001, 7, 1781-821.	1.9	51
93	Synthesis of a hybrid fullereneâ€“trimethoxyindoleâ€“oligonucleotide conjugate. Chemical Communications, 2001, , 17-18.	4.1	31
94	Design, Synthesis, DNA Binding, and Biological Evaluation of Water-Soluble Hybrid Molecules Containing Two Pyrazole Analogues of the Alkylating Cyclopropylpyrroloindole (CPI) Subunit of the Antitumor Agent CC-1065 and Polypyrrole Minor Groove Binders. Journal of Medicinal Chemistry, 2001, 44, 2536-2543.	6.4	78
95	Pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine derivatives: A new pharmacological tool for the characterization of the human A3 adenosine receptor. Drug Development Research, 2001, 52, 406-415.	2.9	10
96	Pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine derivatives as adenosine receptor ligands: A starting point for searching A2B adenosine receptor antagonists. Drug Development Research, 2001, 53, 225-235.	2.9	21
97	Novel Versatile Fullerene Synthons. Journal of Organic Chemistry, 2001, 66, 4915-4920.	3.2	136
98	Pharmacological and biochemical characterization of A3 adenosine receptors in Jurkat T cells. British Journal of Pharmacology, 2001, 134, 116-126.	5.4	100
99	DNA minor groove alkylating agents structurally related to distamycin A. Expert Opinion on Therapeutic Patents, 2000, 10, 891-904.	5.0	2
100	A3 Adenosine Receptor Ligands: History and Perspectives. , 2000, 20, 103-128.		130
101	Synthesis and preliminary biological evaluation of [3H]-MRE 3008-F20: the first high affinity radioligand antagonist for the human A3 adenosine receptors. Bioorganic and Medicinal Chemistry Letters, 2000, 10, 209-211.	2.2	22
102	CC-1065 and the duocarmycins: recent developments. Expert Opinion on Therapeutic Patents, 2000, 10, 1853-1871.	5.0	13
103	Pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine Derivatives as Highly Potent and Selective Human A3Adenosine Receptor Antagonists:Â Influence of the Chain at the N8Pyrazole Nitrogen. Journal of Medicinal Chemistry, 2000, 43, 4768-4780.	6.4	89
104	Design, Radiosynthesis, and Biodistribution of a New Potent and Selective Ligand for in Vivo Imaging of the Adenosine A2A Receptor System Using Positron Emission Tomography. Journal of Medicinal Chemistry, 2000, 43, 4359-4362.	6.4	96
105	Chemical Synthesis of [13C]Daidzein. Journal of Medicinal Food, 1999, 2, 99-102.	1.5	7
106	A1 and A3 adenosine receptor agonists: an overview. Expert Opinion on Therapeutic Patents, 1999, 9, 515-527.	5.0	10
107	Resolution of a CPzI precursor, synthesis and biological evaluation of (+) and (âˆ')-N-Boc-CPzI: A further validation of the relationship between chemical solvolytic stability and cytotoxicity. Bioorganic and Medicinal Chemistry Letters, 1999, 9, 3087-3092.	2.2	15
108	Novel benzoyl nitrogen mustard derivatives of pyrazole analogues of distamycin A: synthesis and antileukemic activity. Bioorganic and Medicinal Chemistry, 1999, 7, 251-262.	3.0	36

#	Article	IF	Citations
109	DNA minor-groove binders: results and design of new antitumor agents. Il Farmaco, 1999, 54, 15-25.	0.9	13
110	Comparative molecular field analysis (CoMFA) of a series of selective adenosine receptor A2A antagonists. Drug Development Research, 1999, 46, 126-133.	2.9	10
111	Selective binding to human genomic sequences of two synthetic analogues structurally related to U-71184 and adozelesin. , 1999, 46, 96-106.		0
112	Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine Derivatives as Highly Potent and Selective Human A3Adenosine Receptor Antagonists. Journal of Medicinal Chemistry, 1999, 42, 4473-4478.	6.4	80
113	Synthesis, in Vitro Antiproliferative Activity, and DNA-Binding Properties of Hybrid Molecules Containing Pyrrolo[2,1-c][1,4]benzodiazepine and Minor-Groove-Binding Oligopyrrole Carriers. Journal of Medicinal Chemistry, 1999, 42, 5131-5141.	6.4	64
114	Design, synthesis and biological activity of a pyrrolo [2,1-c][1,4]benzodiazepine (PBD)-distamycin hybrid. Bioorganic and Medicinal Chemistry Letters, 1998, 8, 3019-3024.	2.2	27
115	Design, Synthesis, and Biological Evaluation of a Second Generation of Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as Potent and Selective A2AAdenosine Receptor Antagonists. Journal of Medicinal Chemistry, 1998, 41, 2126-2133.	6.4	81
116	Synthesis and Biological Activity of a New Series of N6-Arylcarbamoyl, 2-(Ar)alkynyl-N6-arylcarbamoyl, and N6-Carboxamido Derivatives of Adenosine-5â€˜-N-ethyluronamide as A1 and A3 Adenosine Receptor Agonists. Journal of Medicinal Chemistry, 1998, 41, 3174-3185.	6.4	68
117	A _{2A} -Adenosine Receptor Reserve for Coronary Vasodilation. Circulation, 1998, 98, 711-718.	1.6	181
118	1-Methyl-3-nitro-5-methoxycarbonyl Pyrazole. Molecules, 1998, 3, M46.	3.8	3
119	A New Synthetic Approach to Indazole Synthesis. Synthesis, 1997, 1997, 1140-1142.	2.3	21
120	Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine Derivatives:â€‰ Potent and Selective A_{2A}Adenosine Antagonists. Journal of Medicinal Chemistry, 1996, 39, 1164-1171.	6.4	121
121	NovelN6-(Substituted-phenylcarbamoyl)adenosine-5â€˜-uronamides as Potent Agonists for A3Adenosine Receptors. Journal of Medicinal Chemistry, 1996, 39, 802-806.	6.4	48
122	Synthesis of the tritium labeled SCH 58261, a new non-xanthine A2A adenosine receptor antagonist. Journal of Labelled Compounds and Radiopharmaceuticals, 1996, 38, 725-732.	1.0	13
123	4-Isopropyl-2-oxazolin-5-one anion as masked umpoled synthon for both formyl and hydroxycarbonyl anions: Generation, reactivity and synthetic applications. Tetrahedron, 1996, 52, 4719-4734.	1.9	15
124	Synthesis and antitumor activity of novel distamycin derivatives. Bioorganic and Medicinal Chemistry Letters, 1996, 6, 1241-1246.	2.2	16
125	Structure-activity relationship of novel tallimustine derivatives: synthesis and antitumor activity. Bioorganic and Medicinal Chemistry Letters, 1996, 6, 1247-1252.	2.2	18
126	Unusual Ring-Opening Reaction of 6,7-Dihydrothieno[3,2-d]pyrimidine-2,4-dione Derivatives Leading to 5-(Alkylthio)-6-vinyluracils. Journal of Organic Chemistry, 1995, 60, 1461-1463.	3.2	8

#	Article	IF	Citations
127	Mastering .beta.-Keto Esters. Chemical Reviews, 1995, 95, 1065-1114.	47.7	234
128	Enantioselective synthesis of the hexahydronaphthalene nucleus of (â^')-compactin from ethyl (1R,2S)-2-methyl-4-oxocyclohexanecarboxylate and 2-(3-nitropropyl)-1,3-dioxolane as four carbon bifunctional annelating agent.. Tetrahedron, 1994, 50, 11743-11754.	1.9	10
129	Enantioselective synthesis of (â^')-meroquinene through tandem Michael reaction methodology.. Tetrahedron, 1994, 50, 2583-2590.	1.9	25
130	4-Isopropyl-2-oxazolin-5-one anion as a new convenient formyl anion equivalent for conjugate addition and aldol reactions.. Tetrahedron Letters, 1993, 34, 3907-3910.	1.4	24
131	A new approach to kainoids through tandem Michael reaction methodology: application to the enantioselective synthesis of (+)- and (-)-.alpha.-allokainic acid and to the formal synthesis of (-)-.alpha.-kainic acid. Journal of Organic Chemistry, 1992, 57, 6279-6286.	3.2	83
132	A new enantioselective route to kainoids: application to the formal synthesis of (â€“)-Î±-kainic acid. Journal of the Chemical Society Chemical Communications, 1991, , 390-391.	2.0	24
133	Generation and cycloaddition reactions of 3-substituted-2-nitro-1,3-dienes.. Tetrahedron Letters, 1991, 32, 2517-2520.	1.4	31
134	Tandem michael reactions for the construction of pyrrolidine and piperidine ring systems. Tetrahedron Letters, 1990, 31, 3039-3042.	1.4	32
135	Enantioselective synthesis of (+)- and (â^')-Î±-allokainic acid. Tetrahedron Letters, 1990, 31, 4917-4920.	1.4	26